

Tanios S Bekaii-Saab

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9409100/publications.pdf>

Version: 2024-02-01

121
papers

3,056
citations

201385

27
h-index

174990

52
g-index

132
all docs

132
docs citations

132
times ranked

4815
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 276-282.	0.8	524
2	Biliary cancer: Utility of next-generation sequencing for clinical management. <i>Cancer</i> , 2016, 122, 3838-3847.	2.0	289
3	Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 803-815.	3.7	205
4	Appendiceal Mucinous Neoplasms: Diagnosis and Management. <i>Oncologist</i> , 2017, 22, 1107-1116.	1.9	131
5	Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment. <i>Cancer Research</i> , 2017, 77, 2647-2660.	0.4	113
6	Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2. <i>Nature Communications</i> , 2017, 8, 14755.	5.8	96
7	FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements. <i>Future Oncology</i> , 2020, 16, 2385-2399.	1.1	96
8	Prostate cancer incidence in males with Lynch syndrome. <i>Genetics in Medicine</i> , 2014, 16, 553-557.	1.1	88
9	Caveolin-1 is Associated with Tumor Progression and Confers a Multi-Modality Resistance Phenotype in Pancreatic Cancer. <i>Scientific Reports</i> , 2015, 5, 10867.	1.6	87
10	Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype. <i>JCO Precision Oncology</i> , 2018, 2, 1-12.	1.5	86
11	A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. <i>British Journal of Cancer</i> , 2017, 116, 575-583.	2.9	73
12	The Role of Maintenance Strategies in Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2020, 6, e194489.	3.4	65
13	A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2018, 23, 25-34.	1.9	63
14	KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRAS ^{G12C} mutation. <i>Journal of Clinical Oncology</i> , 2022, 40, 519-519.	0.8	60
15	Incidence of Minimally Invasive Colorectal Cancer Surgery at National Comprehensive Cancer Network Centers. <i>Journal of the National Cancer Institute</i> , 2014, 107, dju362-dju362.	3.0	48
16	Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 293-301.	0.6	47
17	Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 3495-3507.	3.2	43
18	Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH). <i>Journal of Clinical Oncology</i> , 2019, 37, 4087-4087.	0.8	42

#	ARTICLE	IF	CITATIONS
19	Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 2403-2413.	3.2	40
20	Systemic Therapy for Advanced Appendiceal Adenocarcinoma: An Analysis From the NCCN Oncology Outcomes Database for Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1123-1130.	2.3	37
21	Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway. <i>Oncogene</i> , 2018, 37, 3440-3455.	2.6	37
22	Quality of Life in a Prospective, Multicenter Phase 2 Trial of Neoadjuvant Full-Dose Gemcitabine, Oxaliplatin, and Radiation in Patients With Resectable or Borderline Resectable Pancreatic Adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 270-277.	0.4	35
23	Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2022, 8, 760.	3.4	35
24	The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma. <i>BioDrugs</i> , 2020, 34, 349-362.	2.2	33
25	ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 3641-3648.	3.2	32
26	Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 344-356.	1.9	31
27	The role of microbiome in pancreatic cancer. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 777-789.	2.7	27
28	A phase I study of MEK inhibitor MEK162 (ARRY-438162) in patients with biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 220-220.	0.8	27
29	Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States. <i>Pancreas</i> , 2020, 49, 193-200.	0.5	26
30	Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. <i>Pancreatology</i> , 2019, 19, 80-87.	0.5	24
31	MOUNTAINEER:open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS153-TPS153.	0.8	24
32	Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer. <i>Investigational New Drugs</i> , 2018, 36, 1037-1043.	1.2	23
33	Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma. <i>Future Oncology</i> , 2018, 14, 553-566.	1.1	22
34	A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma. <i>Investigational New Drugs</i> , 2022, 40, 134-141.	1.2	21
35	<i>BRAF</i> -Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape. <i>Journal of Clinical Oncology</i> , 2022, 40, 2706-2715.	0.8	21
36	Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model. <i>OncImmunology</i> , 2020, 9, 1818437.	2.1	20

#	ARTICLE	IF	CITATIONS
37	AB051. P-19. A phase II study of infigratinib (BGJ398) in previously-treated advanced cholangiocarcinoma containing FGFR2 fusions. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, AB051-AB051.	0.7	18
38	Neoadjuvant Therapy for Rectal Cancer Affects Lymph Node Yield and Status Without Clear Implications on Outcome: The Case for Eliminating a Metric and Using Preoperative Staging to Guide Therapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1528-1534.	2.3	17
39	Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. <i>Pancreatology</i> , 2020, 20, 101-109.	0.5	17
40	Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00414.	1.3	17
41	Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42. <i>Neoplasia</i> , 2016, 18, 765-774.	2.3	16
42	Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma. <i>Cancers</i> , 2018, 10, 193.	1.7	16
43	Practical considerations in the use of regorafenib in metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592095686.	1.4	16
44	MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma—Trial in Progress.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS252-TPS252.	0.8	16
45	Gemcitabine-Associated Thrombotic Microangiopathy: Response to Complement Inhibition and Reinitiation of Gemcitabine. <i>Clinical Colorectal Cancer</i> , 2017, 16, e119-e122.	1.0	14
46	Therapeutic options for intrahepatic cholangiocarcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2017, 6, 91-100.	0.7	13
47	Frontline therapy for advanced hepatocellular carcinoma: an update. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210861.	1.4	13
48	Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination. <i>Pancreatology</i> , 2020, 20, 1115-1122.	0.5	12
49	Causes of Death Following Nonmetastatic Colorectal Cancer Diagnosis in the U.S.: A Population-Based Analysis. <i>Oncologist</i> , 2021, 26, 733-739.	1.9	12
50	IDH1 and IDH2 Driven Intrahepatic Cholangiocarcinoma (IHCC): A comprehensive genomic and immune profiling study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4009-4009.	0.8	11
51	Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy. <i>JCO Precision Oncology</i> , 2022, , .	1.5	11
52	Using Naïve Bayesian Analysis to Determine Imaging Characteristics of KRAS Mutations in Metastatic Colon Cancer. <i>Diagnostics</i> , 2017, 7, 50.	1.3	10
53	The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies. <i>Biomedicines</i> , 2017, 5, 10.	1.4	10
54	Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?. <i>Seminars in Liver Disease</i> , 2021, 41, 136-141.	1.8	10

#	ARTICLE	IF	CITATIONS
55	A SEER-based multi-ethnic picture of advanced intrahepatic cholangiocarcinoma in the United States pre- and post-the advent of gemcitabine/cisplatin. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 1063-1073.	0.6	9
56	Germline Cancer Susceptibility Gene Testing in Unselected Patients with Hepatobiliary Cancers: A Multi-Center Prospective Study. <i>Cancer Prevention Research</i> , 2022, 15, 121-128.	0.7	9
57	Circulating Cell-Free Tumor DNA in Advanced Pancreatic Adenocarcinoma Identifies Patients With Worse Overall Survival. <i>Frontiers in Oncology</i> , 2021, 11, 794009.	1.3	8
58	Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer. <i>International Journal of Cancer</i> , 2018, 142, 1671-1675.	2.3	7
59	A multicenter phase I study of intravenous administration of reolysin in combination with irinotecan/fluorouracil/leucovorin (FOLFIRI) in patients (pts) with oxaliplatin-refractory/intolerant KRAS-mutant metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 450-450.	0.8	7
60	MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinomaâ€”Trial in progress.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS371-TPS371.	0.8	7
61	Novel immunotherapy strategies for hepatobiliary cancers. <i>Immunotherapy</i> , 2018, 10, 1077-1091.	1.0	6
62	Synergistic combination of cytotoxic chemotherapy and cyclinâ€”dependent kinase 4/6 inhibitors in biliary tract cancers. <i>Hepatology</i> , 2022, 75, 43-58.	3.6	6
63	The Continued Struggle for Defining a Role for Radiotherapy in Pancreas Cancer. <i>JAMA Oncology</i> , 2022, 8, 1257.	3.4	6
64	Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma. <i>Oncologist</i> , 2020, 25, e1681-e1690.	1.9	5
65	Survival Benefit of Combination Chemotherapy in Elderly Patients With Metastatic Pancreatic Ductal Adenocarcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 586-590.	0.6	5
66	Nanoliposomal irinotecan (Nal-IRI)-based chemotherapy after irinotecan -based chemotherapy in patients with pancreas cancer. <i>Pancreatology</i> , 2021, 21, 379-383.	0.5	5
67	PULSE: A randomized phase II open label study of panitumumab rechallenge versus standard therapy after progression on anti-EGFR therapy in patients with <i>RAS</i> wild-type metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS143-TPS143.	0.8	5
68	Understanding Suboptimal Response to Immune Checkpoint Inhibitors. <i>Advanced Biology</i> , 2023, 7, e2101319.	1.4	5
69	Signaling pathways as therapeutic targets in biliary tract cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 485-498.	1.5	4
70	FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3797-3805.	1.1	4
71	Sister Mary Joseph Nodule in Advanced Pancreatic Adenocarcinoma Identified on 18F-FDG PET/MRI. <i>Journal of Nuclear Medicine Technology</i> , 2019, 47, 341-342.	0.4	3
72	Phase II randomized, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN G14-198).. <i>Journal of Clinical Oncology</i> , 2021, 39, 413-413.	0.8	3

#	ARTICLE	IF	CITATIONS
73	A phase 1b/2 trial of the PLK1 inhibitor onvansertib in combination with FOLFIRI-bev in 2L treatment of KRAS-mutated (mKRAS) metastatic colorectal carcinoma (mCRC).. Journal of Clinical Oncology, 2022, 40, 100-100.	0.8	3
74	Tepotinib plus cetuximab in patients (pts) with RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC) and acquired resistance to anti-EGFR antibody therapy due to MET amplification (METamp).. Journal of Clinical Oncology, 2021, 39, TPS149-TPS149.	0.8	2
75	FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. JCO Precision Oncology, 2021, 5, 1228-1240.	1.5	2
76	Serial cell-free DNA (cfDNA) sampling in advanced pancreatic ductal adenocarcinoma (PDAC) patients may predict therapeutic outcome.. Journal of Clinical Oncology, 2021, 39, 423-423.	0.8	2
77	A phase II study of biweekly pralatrexate and docetaxel in patients with advanced esophageal and gastroesophageal carcinoma that have failed first-line platinum-based therapy. Journal of Gastrointestinal Oncology, 2015, 6, 336-40.	0.6	2
78	INTEGRATE IIb: A randomized phase III open label study of regorafenib + nivolumab versus standard chemotherapy in refractory advanced gastroesophageal cancer (AGOC).. Journal of Clinical Oncology, 2022, 40, TPS366-TPS366.	0.8	2
79	A randomized phase II trial of MEK and CDK4/6 inhibitors vesus tipiracil/trifluridine (TAS-102) in metastatic <i>KRAS/NRAS</i> mutant (mut) colorectal cancer (CRC).. Journal of Clinical Oncology, 2022, 40, 116-116.	0.8	2
80	ELU-FR \pm -1: A study to evaluate ELU001 in patients with solid tumors that overexpress folate receptor alpha (FR \pm).. Journal of Clinical Oncology, 2022, 40, TPS3158-TPS3158.	0.8	2
81	Competitive Funding Strategies for the Conquer Cancer Foundation of ASCO. Journal of Oncology Practice, 2017, 13, e62-e67.	2.5	1
82	The Role of Maintenance Therapy in Metastatic Colorectal Cancerâ€”Reply. JAMA Oncology, 2020, 6, 937.	3.4	1
83	Baseline albumin (b-alb) as a potential predictive biomarker for the efficacy of bevacizumab (B) therapy (tx) in patients (pts) with advanced pancreas cancer (APCA): A comparative analysis.. Journal of Clinical Oncology, 2012, 30, 4039-4039.	0.8	1
84	Prostate cancer incidence in males with Lynch syndrome.. Journal of Clinical Oncology, 2013, 31, 366-366.	0.8	1
85	AJCC 8th edition staging system for pathologically versus clinically staged intrahepatic cholangiocarcinoma (iCCA): ready for prime time?. Chinese Clinical Oncology, 2019, 8, S19-S19.	0.4	1
86	Phase 1/1b trial of fruquintinib in patients with advanced solid tumors: Preliminary results of the dose expansion cohorts in refractory metastatic colorectal cancer.. Journal of Clinical Oncology, 2022, 40, 93-93.	0.8	1
87	Acquired Immunotherapy Resistance in Gastrointestinal Cancers. JAMA Network Open, 2022, 5, e224646.	2.8	1
88	IMPRINTER: An open label, multicenter, dose escalation/expansion, phase 1 study of imu-201 (PD1-Vaxx), a B-cell immunotherapy as monotherapy or in combination with atezolizumab, in adults with non-small cell lung cancer (IMU.201.101).. Journal of Clinical Oncology, 2022, 40, e21134-e21134.	0.8	1
89	Responses to immune checkpoint inhibition among MSI-H pancreatic ductal adenocarcinoma: A multi-institutional case series.. Journal of Clinical Oncology, 2022, 40, 4145-4145.	0.8	1
90	Taking aim at the genomic diversity of gastrointestinal cancers: a changing landscape. Journal of Gastrointestinal Oncology, 2016, 7, 673-674.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Adjuvant Chemotherapy for Rectal Cancer After Neoadjuvant Treatment: FOLFOX, 5-FU, or Observation. <i>Current Colorectal Cancer Reports</i> , 2016, 12, 260-265.	1.0	0
92	Response to Drs Von Hoff and Renschler. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 445-446.	1.4	0
93	Circulating cell free tumor DNA detection as a prognostic tool in advanced pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4130-4130.	0.8	0
94	Clinical impact of pathogenic germline variants in pancreatic cancer: Results from a multicenter prospective universal genetic testing study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4118-4118.	0.8	0
95	Comparison of Therapy in Advanced Hepatocellular Carcinoma Based on Clear Definition and Accurate Subgroup Dataâ€”Reply. <i>JAMA Oncology</i> , 2021, 7, 941.	3.4	0
96	Gender representation in authorship in later-phase systemic clinical trials in biliary tract cancer (BTC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 348-348.	0.8	0
97	Retrospective analysis of treatment effects and prognostic factors associated with overall survival in patients with resected adenocarcinoma of the pancreas.. <i>Journal of Clinical Oncology</i> , 2012, 30, 359-359.	0.8	0
98	Phase I/II study of ⁹⁰ Y-clivatuzumab tetraxetan (⁹⁰ Y-hPAM4) combined with gemcitabine (Gem) in advanced pancreatic cancer (APC): Final results.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4043-4043.	0.8	0
99	Clinicopathologic feature and outcome of appendiceal goblet cell carcinoid and neuroendocrine tumor.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14170-e14170.	0.8	0
100	A comparative analysis of locoregional therapy (hyperthermic intraperitoneal chemotherapy [HIPEC]) and systemic chemotherapy (CT) following cytoreductive surgery in patients (pts) with disseminated mucinous appendiceal cancers (MACA).. <i>Journal of Clinical Oncology</i> , 2012, 30, e14169-e14169.	0.8	0
101	Masitinib in comparison to imatinib as first-line therapy of patients with advanced gastrointestinal stromal tumor (GIST): A randomized phase III trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS10102-TPS10102.	0.8	0
102	Treatment-related hypertension (HTN) as a predictive biomarker for clinical outcomes in patients (pts) with advanced pancreas cancer (APCA) treated with bevacizumab (B): A pooled analysis of four prospective clinical trials.. <i>Journal of Clinical Oncology</i> , 2013, 31, 239-239.	0.8	0
103	Quality of life in a multicenter phase II trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or borderline resectable pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 226-226.	0.8	0
104	Effectiveness of bevacizumab (BV) beyond disease progression in metastatic colorectal cancer (mCRC): Analyses by sex in the ARIES observational cohort study (OCS).. <i>Journal of Clinical Oncology</i> , 2013, 31, 514-514.	0.8	0
105	REVERCEII (ACCRU-GI-1809): A randomized phase II study of regorafenib followed by anti-EGFR monoclonal antibody therapy versus the reverse sequencing for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin and irinotecan.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS213-TPS213.	0.8	0
106	A phase I study of pharmacokinetic (PK)-driven sequential dosing of rucaparib (RUB) with irinotecan liposome (nal-IRI) and fluorouracil (5FU) in metastatic gastrointestinal (mGI) and pancreas (PANC) cancers.. <i>Journal of Clinical Oncology</i> , 2022, 40, 563-563.	0.8	0
107	SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterationsâ€”Biliary tract cancer cohort.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS489-TPS489.	0.8	0
108	Expanding the arsenal for metastatic colorectal cancer: a discussion of current clinical trials. <i>Clinical Advances in Hematology and Oncology</i> , 2009, 7, 430-2.	0.3	0

#	ARTICLE	IF	CITATIONS
109	Highlights in pancreatic cancer from the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium: commentary. <i>Clinical Advances in Hematology and Oncology</i> , 2018, 16 Suppl 7, 16-18.	0.3	0
110	A treatment landscape in evolution: new strategies, guidelines, and therapeutic advances for metastatic pancreatic adenocarcinoma. <i>Clinical Advances in Hematology and Oncology</i> , 2018, 16 Suppl 17, 5-7.	0.3	0
111	New guideline-sanctioned and emerging interventions for pancreatic cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2018, 16 Suppl 17, 7-9.	0.3	0
112	Cases in the management of metastatic colorectal cancer: sequencing therapies in a patient with the V600E mutation. <i>Clinical Advances in Hematology and Oncology</i> , 2020, 18 Suppl 19, 1-8.	0.3	0
113	Transitioning from second-line to third-line therapy in metastatic colorectal cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19 Suppl 3, 1-20.	0.3	0
114	Proactive transitioning to third-line treatment in metastatic colorectal cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19 Suppl 3, 5-7.	0.3	0
115	Q&A: colorectal cancer in younger patients. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19 Suppl 3, 15-17.	0.3	0
116	Identification of an optimal circulating tumor DNA (ctDNA) shedding threshold to detect actionable driver mutations in colorectal and pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3571-3571.	0.8	0
117	Universal genetic testing versus guideline-directed testing for hereditary cancer syndromes among traditionally underrepresented patients in a community oncology program.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10588-10588.	0.8	0
118	KRAS wild-type pancreatic ductal adenocarcinoma: Molecular and therapeutic opportunities.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4130-4130.	0.8	0
119	ACCRU-GI-2008: A phase II randomized study of atezolizumab (Atezo) plus a multi-kinase inhibitor (MKI) versus MKI alone in patients with unresectable advanced hepatocellular carcinoma (aHCC) who previously received atezolizumab plus bevacizumab (Bev).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4170-TPS4170.	0.8	0
120	Clinical impact of MAPK pathway alterations in advanced biliary tract cancer (BTC): SCRUM-Japan COZILA and COLOMATE international collaboration.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4086-4086.	0.8	0
121	Co-occurring alterations across molecular pathways in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 3590-3590.	0.8	0